Publications

Beltran H.  2014.  The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.. Mol Cancer Res. 12(6):815-22.

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JMiguel, Pauwels J, Park K, Kossai M et al..  2014.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.. Nat Commun. 5:5383.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK et al..  2014.  Organoid cultures derived from patients with advanced prostate cancer.. Cell. 159(1):176-87.

Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera J-M, Reuter VE, Robinson BD, Troncoso P, Rubin MA.  2014.  Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.. Am J Surg Pathol. 38(6):756-67.

Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM et al..  2014.  Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.. Hum Pathol. 45(10):2136-43.

Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera J-M, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA et al..  2014.  Unraveling the clonal hierarchy of somatic genomic aberrations.. Genome Biol. 15(8):439.

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A et al..  2015.  CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.. Oncotarget. 6(14):11994-2008.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A et al..  2015.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.. Cell Rep. 12(6):922-36.

Attard G, Beltran H.  2015.  Prioritizing precision medicine for prostate cancer.. Ann Oncol. 26(6):1041-2.

Beltran H, Demichelis F.  2015.  Prostate cancer: Intrapatient heterogeneity in prostate cancer.. Nat Rev Urol. 12(8):430-1.

Klimstra DS, Beltran H, Lilenbaum R, Bergsland E.  2015.  The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.. Am Soc Clin Oncol Educ Book. :92-103.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopolou E, Chakravarthi BV, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 3(22):298-305.

Beltran H, Antonarakis ES, Morris MJ, Attard G.  2016.  Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.. Am Soc Clin Oncol Educ Book. (35):131-41.

Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. N Engl J Med. 375(5):443-53.

Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf RP, Schreiber NA, Nanus DM et al..  2016.  The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.. Clin Cancer Res. 6(22)

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..  2016.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol.

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 4(30):563-577.

Choe H, Sboner A, Beltran H, Nanus D, Tagawa ST.  2016.  PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.. Thromb Res. 140 Suppl 1:S192.

Beltran H.  2016.  Update on the biology and management of neuroendocrine prostate cancer.. Clin Adv Hematol Oncol. 14(7):513-5.

Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y et al..  2017.  Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.. Cancer Cell. 32(6):792-806.e7.

Rickman DS, Beltran H, Demichelis F, Rubin MA.  2017.  Biology and evolution of poorly differentiated neuroendocrine tumors.. Nat Med. 23(6):1-10.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2017.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer.